Caldaret monohydrate | CAS# 192509-24-3 | Biochemical

MedKoo Cat#: 576929 | Name: Caldaret monohydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Caldaret monohydrate is an intracellular Ca2+ handling modulator that may have cardiotonic effects.

Chemical Structure

Caldaret monohydrate

CAS#192509-24-3

Theoretical Analysis

MedKoo Cat#: 576929

Name: Caldaret monohydrate

CAS#: 192509-24-3

Chemical Formula: C11H18N2O4S

Exact Mass: 274.0987

Molecular Weight: 274.33

Elemental Analysis: C, 48.16; H, 6.61; N, 10.21; O, 23.33; S, 11.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Caldaret monohydrate; MCC-135; MCC 135; MCC135

IUPAC/Chemical Name

Benzenesulfonic acid, 5-methyl-2-(1-piperazinyl)-, monohydrate

InChi Key

ZRQKZWAOIRVBFD-UHFFFAOYSA-N

InChi Code

InChI=1S/C11H16N2O3S.H2O/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13;/h2-3,8,12H,4-7H2,1H3,(H,14,15,16);1H2

SMILES Code

O.Cc1ccc(N2CCNCC2)c(c1)S(=O)(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 274.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Beranek JT. MCC-135 diminishes the egress of CK-MB but not of troponin-I from cardiomyocytes during reperfusion. Ann Thorac Surg. 2005 Mar;79(3):1095; author reply 1095. PubMed PMID: 15734461. 2: Kawasumi H, Satoh N, Kitada Y. Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33. Epub 2007 Feb 14. PubMed PMID: 17299242. 3: Jang IK, Pettigrew V, Picard MH, Kowey PR, Demmel V, Zile MR, Tatsuno J, Wackers FJ, Hibberd M. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study. J Thromb Thrombolysis. 2005 Dec;20(3):147-53. PubMed PMID: 16261287. 4: Satoh N, Kitada Y. Cardioprotective effect of MCC-135 is associated with inhibition of Ca2+ overload in ischemic/reperfused hearts. Eur J Pharmacol. 2004 Sep 19;499(1-2):179-87. PubMed PMID: 15363965. 5: Satoh N, Sato T, Shimada M, Yamada K, Kitada Y. Lusitropic effect of MCC-135 is associated with improvement of sarcoplasmic reticulum function in ventricular muscles of rats with diabetic cardiomyopathy. J Pharmacol Exp Ther. 2001 Sep;298(3):1161-6. PubMed PMID: 11504815. 6: Jang IK, Weissman NJ, Picard MH, Zile MR, Pettigrew V, Shen S, Tatsuno J, Hibberd MG, Tzivoni D, Wackers FJ; EVOLVE Investigators. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan;155(1):113.e1-8. Epub 2007 Nov 1. PubMed PMID: 18082500. 7: Tzivoni D, Balkin J, Bär FW, Hibberd M, Reiber JH, Cowing G. Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2009 Jan 1;103(1):1-4. doi: 10.1016/j.amjcard.2008.08.047. Epub 2008 Oct 23. PubMed PMID: 19101220. 8: Zile M, Gaasch W, Little W, Francis G, Tavazzi L, Cleland J, Davies M; MCC-135 GO1 Investigators. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail. 2004 Jun;10(3):193-9. PubMed PMID: 15190528. 9: Satoh N, Kitada Y. Effects of MCC-135 on Ca2+ uptake by sarcoplasmic reticulum and myofilament sensitivity to Ca2+ in isolated ventricular muscles of rats with diabetic cardiomyopathy. Mol Cell Biochem. 2003 Jul;249(1-2):45-51. PubMed PMID: 12956397. 10: Yarbrough WM, Mukherjee R, Escobar GP, Hendrick JW, Sample JA, Dowdy KB, McLean JE, Mingoia JT, Crawford FA Jr, Spinale FG. Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg. 2003 Dec;76(6):2054-61; discussion 2061. PubMed PMID: 14667641. 11: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 May;30(4):313-31. PubMed PMID: 18773127. 12: Bär FW, Tzivoni D, Dirksen MT, Fernández-Ortiz A, Heyndrickx GR, Brachmann J, Reiber JH, Avasthy N, Tatsuno J, Davies M, Hibberd MG, Krucoff MW; CASTEMI Study Group. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J. 2006 Nov;27(21):2516-23. Epub 2006 Oct 9. PubMed PMID: 17030521. 13: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID: 17805439. 14: Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Aug;1(4):415-23. doi: 10.1016/j.jcin.2008.04.010. PubMed PMID: 19463339. 15: Farr MJ, Lang CC, Lamanca JJ, Zile MR, Francis G, Tavazzi L, Gaasch WH, St John Sutton M, Itoh H, Mancini D; MCC-135 GO1 Investigators. Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol. 2008 Jul 15;102(2):203-6. doi: 10.1016/j.amjcard.2008.03.041. Epub 2008 Jun 12. PubMed PMID: 18602522. 16: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 May;28(4):233-77. PubMed PMID: 16801985. 17: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27. PubMed PMID: 15672123. 18: SoRelle R. Breast-feeding may reduce later blood pressure. Circulation. 2004 Mar 16;109(10):e9017-27. PubMed PMID: 15023898.